4.2 Article

Mechanisms of lenalidomide sensitivity and resistance

Journal

EXPERIMENTAL HEMATOLOGY
Volume 91, Issue -, Pages 22-31

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.exphem.2020.09.196

Keywords

-

Funding

  1. Terry Fox Research Institute
  2. Canadian Institute of Health Research
  3. Genome BC
  4. Genome Canada
  5. Leukemia and Lymphoma Society of Canada
  6. BC Cancer Foundation
  7. John Auston BC Cancer Foundation Clinician-Scientist Award

Ask authors/readers for more resources

The discovery that the immunomodulatory imide drugs (IMiDs) possess antitumor properties revolutionized the treatment of specific types of hematological cancers. Since then, much progress has been made in understanding why the IMiDs are so efficient in targeting the malignant clones in difficult-to-treat diseases. Despite their efficacy, IMiD resistance arises eventually. Herein we summarize the mechanisms of sensitivity and resistance to lenalidomide in del(5q) myelodysplastic syndrome and multiple myeloma, two diseases in which these drugs are at the therapeutic frontline. Understanding the molecular and cellular mechanisms underlying IMiD efficacy and resistance may allow development of specific strategies to eliminate the malignant clone in otherwise incurable diseases. (C) 2020 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available